Evaluation of different recall periods for the US Nationa

Clinical Trials 14, 255-263 DOI: 10.1177/1740774517698645

Citation Report

#	Article	IF	CITATIONS
1	Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Journal of Patient-Reported Outcomes, 2017, 1, 8.	1.9	44
2	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 222-234.	17.8	82
3	Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey. Supportive Care in Cancer, 2018, 26, 1841-1849.	2.2	10
4	Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events. Journal of Patient-Reported Outcomes, 2018, 2, 56.	1.9	4
5	Medical Cannabis Use by Hodgkin Lymphoma Patients: Experience of a Single Center. Acta Haematologica, 2018, 140, 194-202.	1.4	4
6	Different predictors of pain severity across age and gender of a Chinese rural population: a cross-sectional survey. BMJ Open, 2018, 8, e020938.	1.9	8
7	Incorporating Patient-Reported Outcomes Into Early-Phase Trials. , 2018, , 193-208.		3
8	Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer, 2018, 122, 100-106.	2.0	11
9	Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. Journal of Patient-Reported Outcomes, 2019, 3, 19.	1.9	17
10	The development, usability, and reliability of the Electronic Patient Visit Assessment (ePVA) for head and neck cancer. MHealth, 2019, 5, 21-21.	1.6	6
11	Patientâ€reported and clinicianâ€reported chemotherapyâ€induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. Cancer, 2019, 125, 2945-2954.	4.1	60
12	Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. Oncologist, 2019, 24, 762-771.	3.7	56
13	Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and Xâ€linked protoporphyria. JIMD Reports, 2019, 50, 9-19.	1.5	15
14	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenetics and Genomics, 2020, 30, 131-144.	1.5	26
15	Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approach. Cancer Chemotherapy and Pharmacology, 2020, 86, 435-444.	2.3	2
16	Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. JCO Clinical Cancer Informatics, 2020, 4, 947-957.	2.1	97
17	Stereotactic body radiotherapy (SBRT) in patients with lung metastases - prognostic factors and long-term survival using patient self-reported outcome (PRO). BMC Cancer, 2020, 20, 442.	2.6	5
18	Multidimensional Pain Assessment Tools for Ambulatory and Inpatient Nursing Practice. Pain Management Nursing, 2020, 21, 416-422.	0.9	9

#	Article	IF	CITATIONS
19	Chemotherapy-induced nausea in a sample of gynaecological cancer patients: assessment issues and personal risk factors evaluation. Supportive Care in Cancer, 2020, 28, 5343-5351.	2.2	3
21	Preferences of Individuals With Cancer for Patient-Reported Outcome Measures. Oncology Nursing Forum, 2021, 48, 173-183.	1.2	2
22	Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer. Clinical Trials, 2021, 18, 408-416.	1.6	4
23	Development of patient-reported outcomes item set to evaluate acute treatment toxicity to pelvic online magnetic resonance-guided radiotherapy. Journal of Patient-Reported Outcomes, 2021, 5, 47.	1.9	6
24	One-Year Quality of Life Post–Pneumonia Diagnosis in Japanese Adults. Clinical Infectious Diseases, 2021, 73, 283-290.	5.8	20
25	Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAEâ,,¢). Journal of Patient-Reported Outcomes, 2020, 4, 81.	1.9	5
26	The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. Journal of Patient-Reported Outcomes, 2020, 4, 88.	1.9	19
27	Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. JMIR Human Factors, 2018, 5, e10070.	2.0	20
28	Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients' and Clinicians' Experiences. Journal of Medical Internet Research, 2020, 22, e14896.	4.3	24
29	Research Methods: Quality of Life and Patient-Reported Outcome Research in Geriatric Oncology. , 2018, , 1-10.		0
32	New Developments in the Use of Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies. Advances in Experimental Medicine and Biology, 2020, 1244, 335-339.	1.6	4
33	Research Methods: Quality of Life and Patient-Reported Outcome Research in Geriatric Oncology. , 2020, , 1105-1113.		1
34	Feasibility, usability and acceptance of weekly electronic patient-reported outcomes among patients receiving pelvic CT- or online MR-guided radiotherapy – A prospective pilot study. Technical Innovations and Patient Support in Radiation Oncology, 2022, 21, 8-15.	1.9	6
35	Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study. JMIR Formative Research, 2022, 6, e27775.	1.4	2
36	Assessment of Patient Reported Outcomes (PROs) in Outpatients Taking Oral Anticancer Drugs Included in the Real-Life Oncoral Program. Cancers, 2022, 14, 660.	3.7	3
37	Analysis of a Remote Monitoring Program for Symptoms Among Adults With Cancer Receiving Antineoplastic Therapy. JAMA Network Open, 2022, 5, e221078.	5.9	19
39	Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials. Clinical Trials, 2022, 19, 274-276.	1.6	3
40	Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events. Clinical Trials, 2022, 19, 267-273.	1.6	5

CITATION REPORT

ARTICLE IF CITATIONS # Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology 1.1 3 41 Criteria for Adverse Event (PRO-CTCAE®). Tumori, 0, , 030089162210995. Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. Biomedicines, 42 3.2 2022, 10, 1334. Autoavaliação de Sintomas pelo Paciente com Câncer: a Hora é Agora. Revista Brasileira De 43 0.3 0 Cancerologia, 2022, 68, . Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria—a pilot study (ePRO-AA-PNH). Annals of Hematology, 2023, 102, 199-208. 1.8 The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision 45 2.8 4 medicine. Frontiers in Oncology, 0, 12, . Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE® to Provide Two Distinct and Complementary Perspectives. Patient Related Outcome 1.2 Measures, 0, Volume 13, 249-258. Recommendations on the use of item libraries for patient-reported outcome measurement in oncology 47 trials: findings from an international, multidisciplinary working group. Lancet Oncology, The, 2023, 10.7 13 24, e86-e95. Systematic Review of the Effect of a One-Day Versus Seven-Day Recall Duration on Patient Reported 2.7 Óutcome Measures (PROMs). Patient, 2023, 16, 201-221. GSTM1 and GSTT1 polymorphisms associated with pain in a chemotherapy-induced peripheral 49 2.5 0 neuropathy cohort. Journal of Cancer Research and Clinical Oncology, 0, , . Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period. Quality of Life 3.1 Research, 2023, 32, 2047-2058. The iBLAD app protocol – a national, exploratory study on a multimodality smartphone app in bladder cancer for better understanding symptoms, quality of life and need for supportive care. Acta 51 0 1.8 OncolÃ³gica, 2023, 62, 329-333. Umbilical Cord Mesenchymal Stromal Cells for Steroid-Refractory Acute Graft-versus-Host Disease. 3.8 Pharmaceuticals, 2023, 16, 512. Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events 54 1.9 3 (irAEs) in Cancer Treatment. Cancer Informatics, 2023, 22, 117693512311785. Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial. JMIR Research 1.0 Protocols, 0, 12, e48386. Patient-Reported Outcomes in Clinical Trials: From an Endpoint to an Intervention in Cancer Care. 2.2 0 56 Seminars in Radiation Oncology, 2023, 33, 358-366. Adverse Event Assessment and Reporting in Exercise Oncology: A Review., 2023, 1, 1-7. Evaluating Recall Periods for Patient-Reported Outcome Measures: AÂSystematic Review of Quantitative 58 0.3 0 Methods. Value in Health, 2024, 27, 518-526.

CITATION REPORT